Skip Navigation


Annals of Oncology Advance Access originally published online on November 1, 2006
Annals of Oncology 2007 18(2):317-323; doi:10.1093/annonc/mdl377
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/2/317    most recent
mdl377v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (50)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ohe, Y
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohe, Y
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

lung cancer

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

Y Ohe1,*, Y Ohashi2, K Kubota3, T Tamura1, K Nakagawa4, S Negoro5, Y Nishiwaki3, N Saijo3, Y Ariyoshi6, M Fukuoka4 and For the FACS Cooperative Group

1 Department of Internal Medicine, National Cancer Center Hospital, Tokyo
2 Department of Biostatistics/Epidemiology and Preventive Health Sciences, School of Health Sciences and Nursing, The University of Tokyo, Tokyo
3 Thoracic Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba
4 Department of Medical Oncology, Kinki University School of Medicine, Osakasayama, Osaka
5 Department of Thoracic Oncology, Hyogo Medical Center for Adults, Akashi, Hyogo
6 Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan

* Correspondence to: Dr Y. Ohe, Department of Internal Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Tel: +81-3-3542-2511; Fax: x+81-3-3542-7006; E-mail: yohe{at}ncc.go.jp

Background: To compare the efficacy and toxicity of three platinum-based combination regimens against cisplatin plus irinotecan (IP) in patients with untreated advanced non-small-cell lung cancer (NSCLC) by a non-inferiority design.

Patients and methods: A total of 602 patients were randomly assigned to one of four regimens: cisplatin 80 mg/m2 on day 1 plus irinotecan 60 mg/m2 on days 1, 8, 15 every 4 weeks (IP) carboplatin AUC 6.0 min x mg/mL (area under the concentration–time curve) on day 1 plus paclitaxel 200 mg/m2 on day 1 every 3 weeks (TC); cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1, 8 every 3 weeks (GP); and cisplatin 80 mg/m2 on day 1 plus vinorelbine 25 mg/m2 on days 1, 8 every 3 weeks (NP).

Results: The response rate, median survival time, and 1-year survival rate were 31.0%, 13.9 months, 59.2%, respectively, in IP; 32.4%, 12.3 months, 51.0% in TC; 30.1%, 14.0 months, 59.6% in GP; and 33.1%, 11.4 months, 48.3% in NP. No statistically significant differences were found in response rate or overall survival, but the non-inferiority of none of the experimental regimens could be confirmed. All the four regimens were well tolerated.

Conclusion: The four regimens have similar efficacy and different toxicity profiles, and they can be used to treat advanced NSCLC patients.

Key words: carboplatin, cisplatin, gemcitabine, irinotecan, non-small-cell lung cancer, paclitaxel, randomized phase III study, vinorelbine

Received for publication May 16, 2006. Revision received August 13, 2006. Accepted for publication August 30, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JCOHome page
K. Takeda, T. Hida, T. Sato, M. Ando, T. Seto, M. Satouchi, Y. Ichinose, N. Katakami, N. Yamamoto, S. Kudoh, et al.
Randomized Phase III Trial of Platinum-Doublet Chemotherapy Followed by Gefitinib Compared With Continued Platinum-Doublet Chemotherapy in Japanese Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203)
J. Clin. Oncol., February 10, 2010; 28(5): 753 - 760.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
T. Mitsudomi
Advances in Target Therapy for Lung Cancer
Jpn. J. Clin. Oncol., February 1, 2010; 40(2): 101 - 106.
[Abstract] [Full Text] [PDF]


Home page
J Oncol PractHome page
M. A. Neubauer, J. R. Hoverman, M. Kolodziej, L. Reisman, S. K. Gruschkus, S. Hoang, A. A. Alva, M. McArthur, M. Forsyth, T. Rothermel, et al.
Cost Effectiveness of Evidence-Based Treatment Guidelines for the Treatment of Non-Small-Cell Lung Cancer in the Community Setting
J. Oncol. Pract, January 1, 2010; 6(1): 12 - 18.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Yamada, K. Matsumoto, W. Wang, Q. Li, Y. Nishioka, Y. Sekido, S. Sone, and S. Yano
Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer
Clin. Cancer Res., January 1, 2010; 16(1): 174 - 183.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. G. Azzoli, S. Baker Jr, S. Temin, W. Pao, T. Aliff, J. Brahmer, D. H. Johnson, J. L. Laskin, G. Masters, D. Milton, et al.
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer
J. Clin. Oncol., December 20, 2009; 27(36): 6251 - 6266.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
T. Fujii, H. Kunikane, H. Okamoto, K. Watanabe, H. Kunitoh, K. Mori, A. Yokoyama, H. Fukuda, T. Tamura, and N. Saijo
A Phase II Study of Cisplatin and Irinotecan as Induction Chemotherapy Followed by Accelerated Hyperfractionated Thoracic Radiotherapy with Daily Low-dose Carboplatin in Unresectable Stage III Non-small Cell Lung Cancer: JCOG 9510
Jpn. J. Clin. Oncol., December 1, 2009; 39(12): 784 - 790.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
A. Hiramatsu, Y. Iwasaki, Y. Koyama, N. Tamiya, S. Hosogi, M. Nakanishi, Y. Kohno, M. Ueda, T. Arimoto, and Y. Marunaka
Phase II Trial of Weekly Gemcitabine and Split-dose Cisplatin for Advanced Non-small-cell Lung Cancer
Jpn. J. Clin. Oncol., December 1, 2009; 39(12): 779 - 783.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. Wang, Q. Li, T. Yamada, K. Matsumoto, I. Matsumoto, M. Oda, G. Watanabe, Y. Kayano, Y. Nishioka, S. Sone, et al.
Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Clin. Cancer Res., November 1, 2009; 15(21): 6630 - 6638.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
T. Sakakibara, A. Inoue, S. Sugawara, M. Maemondo, T. Ishida, K. Usui, T. Abe, M. Kanbe, H. Watanabe, Y. Saijo, et al.
Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer
Ann. Onc., October 8, 2009; (2009) mdp401v1.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H. West, D. Harpole, and W. Travis
Histologic Considerations for Individualized Systemic Therapy Approaches for the Management of Non-small Cell Lung Cancer
Chest, October 1, 2009; 136(4): 1112 - 1118.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
Y. W. MOON, J. H. SOHN, Y. T. KIM, H. CHANG, J. H. JEONG, Y. J. LEE, J. CHANG, S. K. KIM, M. JUNG, S. HONG, et al.
Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided versus Empirical Chemotherapy in Unresectable Non-small Cell Lung Cancer
Anticancer Res, October 1, 2009; 29(10): 4243 - 4249.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
K. Naoki, H. Kunikane, T. Fujii, S. Tsujimura, N. Hida, H. Okamoto, and K. Watanabe
Dose-escalating and Pharmacokinetic Study of a Weekly Combination of Paclitaxel and Carboplatin for Inoperable Non-small Cell Lung Cancer: JCOG 9910-DI
Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 569 - 575.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. R. Gandara, T. Kawaguchi, J. Crowley, J. Moon, K. Furuse, M. Kawahara, S. Teramukai, Y. Ohe, K. Kubota, S. K. Williamson, et al.
Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics
J. Clin. Oncol., July 20, 2009; 27(21): 3540 - 3546.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Nagano, M. Yasunaga, K. Goto, H. Kenmotsu, Y. Koga, J.-i. Kuroda, Y. Nishimura, T. Sugino, Y. Nishiwaki, and Y. Matsumura
Antitumor Activity of NK012 Combined with Cisplatin against Small Cell Lung Cancer and Intestinal Mucosal Changes in Tumor-Bearing Mouse after Treatment
Clin. Cancer Res., July 1, 2009; 15(13): 4348 - 4355.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
T. HIROSE, T. SUGIYAMA, S. KUSUMOTO, T. SHIRAI, M. NAKASHIMA, T. YAMAOKA, K. OKUDA, K. OGURA, T. OHNISHI, T. OHMORI, et al.
Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer
Anticancer Res, May 1, 2009; 29(5): 1733 - 1738.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
F. Grossi, M. Aita, C. Defferrari, F. Rosetti, A. Brianti, G. Fasola, O. Vinante, P. Pronzato, and G. Pappagallo
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
Oncologist, May 1, 2009; 14(5): 497 - 510.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
T. Shukuya, T. Takahashi, A. Tamiya, A. Ono, S. Igawa, A. Tsuya, Y. Nakamura, H. Murakami, T. Naito, K. Kaira, et al.
Evaluation of the Safety and Compliance of 3-Week Cycles of Vinorelbine on Days 1 and 8 and Cisplatin on Day 1 as Adjuvant Chemotherapy in Japanese Patients with Completely Resected Pathological Stage IB to IIIA Non-small Cell Lung Cancer: A Retrospective Study
Jpn. J. Clin. Oncol., March 1, 2009; 39(3): 158 - 162.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Yano, W. Wang, Q. Li, K. Matsumoto, H. Sakurama, T. Nakamura, H. Ogino, S. Kakiuchi, M. Hanibuchi, Y. Nishioka, et al.
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
Cancer Res., November 15, 2008; 68(22): 9479 - 9487.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. Okamoto, T. Nishimura, M. Miyazaki, H. Yoshioka, A. Kubo, K. Takeda, N. Ebi, S. Sugawara, N. Katakami, M. Fukuoka, et al.
Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non-Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505
Clin. Cancer Res., August 15, 2008; 14(16): 5250 - 5254.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Ohe, Y. Ichinose, K. Nakagawa, T. Tamura, K. Kubota, N. Yamamoto, S. Adachi, Y. Nambu, T. Fujimoto, Y. Nishiwaki, et al.
Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2008; 14(13): 4206 - 4212.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R. Rosell, G. Robinet, A. Szczesna, R. Ramlau, M. Constenla, B. C. Mennecier, W. Pfeifer, K. J. O'Byrne, T. Welte, R. Kolb, et al.
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
Ann. Onc., February 1, 2008; 19(2): 362 - 369.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
D. J. Kerr Editor-in-
New wave
Ann. Onc., January 1, 2008; 19(1): 3 - 4.
[Full Text] [PDF]


Home page
The OncologistHome page
S. Ramalingam and C. Belani
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Oncologist, January 1, 2008; 13(suppl_1): 5 - 13.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. O. Park, S.-W. Kim, J. S. Ahn, C. Suh, J. S. Lee, J. S. Jang, E. K. Cho, S. H. Yang, J.-H. Choi, D. S. Heo, et al.
Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non Small-Cell Lung Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5233 - 5239.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
H. Takatani, H. Soda, Y. Nakamura, A. Kinoshita, M. Fukuda, S. Nagashima, M. Fukuda, Y. Soejima, H. Nakano, M. Oka, et al.
Phase I Study of Irinotecan and Gemcitabine in Previously Untreated Patients with Advanced Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., May 1, 2007; 37(5): 353 - 357.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.